12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sofosbuvir: Phase III data

Top-line data from the open-label, U.S. and Puerto Rican Phase III NEUTRINO trial in 327 treatment-naïve patients with chronic HCV genotype 1, 4, 5 or 6 infection showed that once-daily 400 mg sofosbuvir plus ribavirin and peginterferon alfa-2a for 12 weeks met the primary endpoint of improving SVR12 rate vs. a predefined historical control SVR12 rate (90% vs. 60%, p<0.001). SVR12 rates were 89% in patients with HCV genotype 1 infection and 97% in patients with...

Read the full 358 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >